| NOVO NORDISK A/S Patent applications |
| Patent application number | Title | Published |
|---|
| 20120135920 | Preparation Comprising Insulin, Nicotinamide and an Amino Acid - Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid. | 05-31-2012 |
| 20120135519 | INDUCED DERIVATION OF SPECIFIC ENDODERM FROM hPS CELL-DERIVED DEFINITIVE ENDODERM - The present invention relates to a method to control differentiation of human pluripotent stem cells, including human balstocyst derived stem (hBS) cells and to obtain specific endoderm cells. In particular, present invention relates to the use of FGF2 as the key factor in a specific concentration to control differentiation of definitive endoderm cells derived from hPS cells to specific endoderm cells. The invention also provides methods of obtaining endoderm cells comprising the use of FGFR and activation of the MAPK signalling pathway. | 05-31-2012 |
| 20120132572 | SPHERICAL ENCODED BEADS - The present application discloses spherical polymer bead comprising embedded therein an ultrasonic identification chip, said chip comprising one or more resonator cavities, the dimensions of each of the one or more resonator cavities giving rise to an ultrasonic resonance frequency of 20 kHz or more. The application also discloses a bead sorting apparatus equipped with at least one ultrasonic transmitter and at least one ultrasonic receiver, and a method of measuring the ultrasonic code of an ultrasonic encoded bead using the bead sorting apparatus. | 05-31-2012 |
| 20120109071 | MEDICAL DELIVERY DEVICE WITH TIME LAPSE INDICATOR - The present invention relates to medical delivery devices for administering a dose of a drug into the body of a subject user and incorporating a time lapse indicator which is configured for indicating after administration that a dose of the drug actually has been administered and for maintaining this indication until lapse of a pre-defined time interval. The time lapse indicator disclosed is based on a pressure sensitive substance which exhibits a change in a visual property in response to an action associated with administering a dose and wherein the pressure sensitive substance exhibits a further change in a visual property after lapse of a pre-defined time interval subsequent to said action. | 05-03-2012 |
| 20120109046 | SOLID DOSE DELIVERY DEVICE - The invention relates to a medicament delivery device ( | 05-03-2012 |
| 20120107867 | GLYCOPEGYLATED ERYTHROPOIETIN - The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates. | 05-03-2012 |
| 20120107267 | INTERLEUKIN-21 VARIANTS HAVING ANTAGONISTIC BINDING TO THE IL-21 RECEPTOR - The invention relates to isolated IL-21 variant peptides having antagonistic binding to the common gamma chain (yC) of the IL-21 receptor, to pharmaceutical compositions comprising said peptides and to the use of said peptides in therapy. | 05-03-2012 |
| 20120101470 | MEDICAL DEVICE AND CARTRIDGE - A cartridge is engageable with a medical device, the cartridge comprising an ordered arrangement of N electrical components ( | 04-26-2012 |
| 20120095410 | Dial-Down Mechanism for Wind-Up Pen - The present invention relates to a dial-down mechanism for an injection device comprising a torsion spring for assisting injection of a dose of medicament from the injection device, the dial-down mechanism comprising a ratchet arm ( | 04-19-2012 |
| 20120093840 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS - The invention described herein relates to novel molecules and polypeptides comprising at least one amino acid sequence having significant identity with (homology to) human Factor VIII or biologically active portion(s) thereof, related molecules (such as nucleic acids encoding such polypeptides), compositions (such as pharmaceutical formulations) comprising such polypeptides, and methods of making and using such polypeptides. | 04-19-2012 |
| 20120088716 | Polypeptide Protracting Tags - Method for increasing half-life of compounds in plasma and novel derivatives of such compounds. | 04-12-2012 |
| 20120083746 | Automatic Injection Device with a Top Release Mechanism - The present invention relates to a handheld mechanical injection device by which set doses of a liquid medicament can be injected from a medical reservoir. The medicament is expelled through an injection needle by release of a power reservoir in the device, the power reservoir being fully or partially released by actuation of a user operable release member being positioned at or near an upper end of the injection device, the upper end being that end of the injection device which is opposite the injection needle. | 04-05-2012 |
| 20120083600 | NUCLEOTIDE SUGAR PURIFICATION USING MEMBRANES - The invention provides methods of removing contaminants from a mixture of a desired product and contaminants by pH adjustments and molecular weight cut-offs. The contaminants include phosphate groups, magnesium sulfate, sodium pyruvate and tetrasodium pyrophosphate groups. The desired product includes nucleotide sugars, glycolipids, LnNT, sialyl lactose, and salts. | 04-05-2012 |
| 20120083027 | Basic Protein Purification Tags from Thermophilic Bacteria - The invention is related to a method for purification of recombinant proteins using highly basic proteins from thermophilic bacteria as purification tags for use in a cation-exchange chromatography purification step. The basic proteins may be ribosomal proteins. The recombinant proteins are expressed in eukaryotic or prokaryotic host cells. The purification tag will typically have a pl above about 9 and comprise from about 15 to about 250 amino acid residues. | 04-05-2012 |
| 20120082724 | DRY MOULDABLE DRUG FORMULATION - Solid pharmaceutical compositions for parenteral injection comprising a binder and at least one therapeutic agent. The pharmaceutical composition has the strength to be injected directly with the need of using cannulas or the like. | 04-05-2012 |
| 20120078194 | Injection Device with Electronic Detecting Means - An injection device for injecting a dose of drug, e.g. insulin for diabetes treatment, in which energy is stored in a spring member during dose setting. The stored energy is released and used for driving an injection mechanism during injection of a previously set dose. The injection device further comprises means for electronically detecting the amount of a set dose and/or means for electronically detecting the amount of an injected dose. The electronic detecting means allows storage and/or logging of data relating to injections performed using the injection device. | 03-29-2012 |
| 20120071402 | Protease Stabilized, Pegylated Insulin Analogues - Novel PEGylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H. The PEGylation is at B29K. | 03-22-2012 |
| 20120041174 | Counter Current Purification of Polypeptides - The present invention relates to methods for the purification of polypeptides using counter current chromatography. In particular the present invention relates to the use of counter current chromatography for the purification of recombinant GLP-1. | 02-16-2012 |
| 20120035104 | Insulin derivatives - The present invention relates to insulin derivatives having a side chain attached either to the α-amino group of the N-terminal amino acid residue of the B chain or to the ε-amino group of a Lys residue present in the B chain of the parent insulin via an amide bond which side chain comprises at least one aromatic group; at least one free carboxylic acid group or a group which is negatively charged at neutral pH, a fatty acid moiety with 4 to 22 carbon atoms in the carbon chain; and possible linkers which link the individual components in the side chain together via amide bonds. | 02-09-2012 |
| 20120035099 | FGF21 ANALOGUES AND DERIVATIVES - Derivatives of Fibroblast Growth Factor 21 which have improved properties for treating diabetes can be prepared by a recombinant process. | 02-09-2012 |
| 20120021973 | Peptides for Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity. | 01-26-2012 |
| 20120018298 | Electrolytic CIP-Cleaning Process for Removing Impurities from the Inner Surface of a Metallic Container - The invention relates to a novel electrolytic process for removing impurities from the inner surface of a metallic container. The process is particularly useful for cleaning process reactors used for culturing microorganisms, and storage tanks used for storing metabolites formed in the process reactor, as well as containers for dairy products. | 01-26-2012 |
| 20120016315 | NEEDLE MAGAZINE - A needle magazine for holding a plurality of injection needles ( | 01-19-2012 |
| 20120016105 | PURIFICATION OF PEPTIDE CONJUGATES BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY - The present invention provides polypeptides that include an O-linked glycosylation site that is not present in the wild-type peptide. The polypeptides of the invention include glycoconjugates in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue to the polypeptide. Also provided are methods of making a glycoconjugate, methods of isolating a glycoconjugate from a reaction mixture, pharmaceutical compositions containing a glycoconjugate, and methods of treating, ameliorating or preventing diseased in mammals by administering an amount of a glycoconjugate sufficient to achieve the desired response. | 01-19-2012 |
| 20120015867 | THERAPEUTIC PEPTIDES AND METHOD - A polypeptide comprising one or more sequences derived from CDR2 or CDR3 of a TREM-1 protein, characterised by the ability to treat, ameliorate, or lessen the symptoms of conditions including sepsis, septic shock or sepsis-like conditions and IBD. | 01-19-2012 |
| 20120012499 | TABLET FORMULATION - The present invention relates to a pharmaceutical fixed dose combination tablet comprising repaglinide and metformin. The present invention also provides a method of producing said tablet. | 01-19-2012 |
| 20120004176 | Liquid Composition of Factor VII Polypeptides - A liquid aqueous composition comprising (i) a factor VII polypeptide, (ii) an agent suitable for keeping pH in the range of from about 4.0 to about 8.0; (iii) an agent selected from the list of: a calcium salt, a magnesium salt, or a mixture thereof; wherein the concentration of (iii) is at least 15 mM. | 01-05-2012 |
| 20110319592 | Process for the Purification of Antibodies Using Affinity Resins Comprising Specific Ligands - The present invention relates to a novel process for the purification of antibodies, e.g. monoclonal antibodies. The process utilizes an affinity resin comprising a solid phase material having immobilized thereto one or more low-molecular weight synthetic ligands. The affinity resins enable the separation of antibodies from even closely related proteins. | 12-29-2011 |
| 20110319591 | PEGYLATED, EXTENDED INSULINS - PEGylated, extended insulins are insulins which, compared with human insulin, has one or more extensions extended from the A1, B1, A21 and/or B30 position(s), said extension(s) consist(s) of amino acid residue(s) and wherein a PEG moiety, via a linker, is attached to one or more of the amino acid residues in the extension(s). PEG is polyethyleneglycol. Such PEGylated, extended insulins have higher bioavailability and a longer time-action profile than regular insulin and are in particular suited for pulmonary administration and can, conveniently, be used to treat diabetes. | 12-29-2011 |
| 20110318356 | Antibodies Against Tissue Factor Pathway Inhibitor - The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy. | 12-29-2011 |
| 20110306551 | Modification of Factor VIII - A Factor VIII derivative of formula (I): wherein: B represents C | 12-15-2011 |
| 20110301158 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS - This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. | 12-08-2011 |
| 20110301084 | Protracted Exendin-4 Compounds - Novel protracted exendin-4 compounds and therapeutic uses thereof. | 12-08-2011 |
| 20110295218 | BENDED INJECTION NEEDLE - A method of manufacturing a bended injection needle assembly comprising the steps of: mounting a straight one-piece metallic needle cannula ( | 12-01-2011 |
| 20110295215 | MEDICAL ASSEMBLY WITH MONITORING DEVICE - An assembly comprises a drug delivery device and a monitoring device adapted to detect an action taking place in the drug delivery device. The drug delivery device comprises a main portion having a drug expelling mechanism for expelling drug from a reservoir through an outlet, a housing in which at least a portion of the expelling mechanism is arranged, and coupling means for a cover. The cover is adapted to cover the outlet when mounted on the main portion. The monitoring device comprises a housing portion, means for detecting an action taking place in the drug delivery device, and coupling means adapted to engage the coupling means on the main portion. By this arrangement the monitoring device can be placed in a pre-determined position relative to the main portion when the coupling means engage each other, this allowing efficient transmission of information between the monitoring device and the main portion. | 12-01-2011 |
| 20110294852 | Pharmaceutical Formulation Comprising Metformin and Repaglinide - The invention is related to a pharmaceutical composition comprising repaglinide in combination with metformin or a salt thereof in unit dosage form wherein a pre-formulation of the repaglinide has a pH independent dissolution profile and a relative humidity of less than about 25% prior to mixing with the metformin or a salt thereof; and optionally one or more pharmaceutically acceptable excipients and to a method for its preparation. | 12-01-2011 |
| 20110294729 | Novel Insulin Analogues - Insulin analogues wherein the B25 amino acid residue is His or Asn with the proviso that if the B25 amino acid residue is His, then the B27 amino acid residue is Asp or Glu and the A14 amino acid residue is different from Glu, have liver preferential actions. | 12-01-2011 |
| 20110293714 | PHARMACEUTICAL COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION OF DERIVATIZED INSULIN PEPTIDES - The invention is related to a water-free liquid or semisolid pharmaceutical composition comprising a derivatized insulin peptide, at least one polar organic solvent and at least one lipophilic component and a method of treatment using such. | 12-01-2011 |
| 20110293561 | ANTI-KIR COMBINATION TREATMENTS AND METHODS - Compositions comprising anti-KIR antibodies and one or more secondary anti-cancer agents or anti-viral agents and methods of using such combinations (as combination compositions or in separate administration protocols) in the treatment of cancers (e.g., lung cancer) or viral infection (e.g., HIV or HCV infection) are provided. | 12-01-2011 |
| 20110286977 | G6PC2-Encoded Beta Cell Surface Tags - The invention relates to G6PC2-encoded beta cell surface markers, methods of identifying and obtaining a culture cells comprising fully differentiated beta cells. Also contemplated is a method of sorting such cells, isolated cells and compositions thereof. | 11-24-2011 |
| 20110275559 | Long-Acting Y2 and/or Y4 Receptor Agonists - The present invention relates to a PYY or PP peptide derivative or analogue thereof derivatised with one or more serum albumin binding side chains comprising a dis-tal tetrazole or carboxylic acid group. Moreover, the invention relates to compositions hereof and methods of treatment of conditions responsive to Y receptor modulation. | 11-10-2011 |
| 20110270217 | Skin Retention Device for a Medical Jet Injection Kit - A skin retention device | 11-03-2011 |
| 20110270214 | ELECTRONICALLY ASSISTED DRUG DELIVERY DEVICE - The present invention relates to electronically assisted drug delivery devices ( | 11-03-2011 |
| 20110269182 | Method for Selectively Modifying a Protein - The present invention relates generally to a novel method of introducing property modifying groups to a protein. In particular, the present invention relates to the derivatization of lysine residues, as well as new conjugates of growth hormones with improved pharmacological properties, and methods for their preparation and use in therapy. | 11-03-2011 |
| 20110268745 | Antibodies Against Tissue Factor Pathway Inhibitor (TFPI) - The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce clotting time in (a) human FVIII-deficient plasma and/or (b) human whole blood. Such antibodies have utility in the treatment of bleeding disorders and in the stimulation of blood clotting. | 11-03-2011 |
| 20110264046 | Method for Ensuring Constant Speed of a Motor in an Injection Device - The present invention relates to a method for ensuring a constant target speed of a battery driven electrical motor, the battery driven electrical motor being adapted to move a piston rod in an injection device so as to inject a set dose of medicine from the injection device, the method comprising the steps of setting a first target speed to be reached by the motor, determining whether the first target speed can be reached, and, if the first target speed can be reached, maintaining the first target speed until a set dose of medicine has been injected from the injection device, or if the first target speed cannot been reached, setting a second target speed. | 10-27-2011 |
| 20110259774 | COVER WITH DEVICE ACTUATION FEATURE - The invention provides an assembly comprising a cover and a device arranged fully or partly in the cover. The device comprises a first portion, and a second portion moveable relative to the first portion between an initial and an actuated position, and the cover comprises a cavity portion and a closure portion which together form an enclosure in which the device is arranged initially. Movement of the closure portion from an initial position in a first direction results in the second portion of the device being moved in a second direction between the initial and the actuated position, the first direction being different from the second direction. By this arrangement it is possible to provide a cover-device assembly which is easy and intuitive to use and open and at the same time ensures that the enclosed device is actuated correctly. | 10-27-2011 |
| 20110256020 | Method and an Apparatus for Sterilizing Packaging Material - A method and an apparatus for sterilizing packaging material for use in packaging for protein containing products, such as food products or medical drugs. The packaging material is sterilized by irradiating it using a beam of ionizing radiation, such as an electron beam or a beam of gamma rays. Afterwards, the packaging material is processed in such a manner that protein reactive substances or compounds formed in the packaging material during the irradiation step are at least partly removed or rendered inreactive with respect to proteins. The processing step may advantageously be performed by heating the packaging material. Preferably, the processing step involves accelerating diffusion from the packaging material of protein reactive substances or compounds. | 10-20-2011 |
| 20110245163 | Stabilised Insulin Compositions - The present invention relates to human insulin analogues having a fast onset of action. These analogues may have amino acid in position B26 substituted with Phe, or be Des(B30) analogues of human insulin. The invention also relates to compositions comprising such insulin analogues, and to compositions comprising a mixture of an insulin analogue having a fast onset of action and insulin having a protracted action. | 10-06-2011 |
| 20110237673 | Novel NIDDM Regimen - The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone. | 09-29-2011 |
| 20110236929 | E. COLI BL21 STRAIN LACKING A FUNCTIONAL GROUP II CAPSULAR GENE CLUSTER - The present invention relates to a novel non-pathogenic | 09-29-2011 |
| 20110230409 | GLP-I Agonist And Cardiovascular Complications - Methods and uses for the treatment and prevention of cardiac and cardiovascular diseases comprising administration of a GLP-1 agonist. | 09-22-2011 |
| 20110230402 | TREATING DIABETES MELITUS USING INSULIN INJECTIONS WITH LESS THAN DAILY INJECTION FREQUENCY - The present invention relates to an insulin derivative for the treatment of a condition or disease where administration of insulin will be of benefit, comprising administering, to a patient in need thereof, effective dosages of the insulin derivative, wherein said insulin derivative exhibits a prolonged profile of action and wherein said dosages are administered at intervals longer than 24 hours. | 09-22-2011 |
| 20110213131 | Method of Acylating a Peptide or Protein - A method has for selectively acylating an amino group in a peptide or protein which has two or more reactive nucleophilic functional groups is described. | 09-01-2011 |
| 20110213125 | Humanized Antibodies Against Human Interferon-Alpha - The present invention provides humanized anti-human IFN-α monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof. | 09-01-2011 |
| 20110208125 | MEDICAL INJECTION DEVICE WITH TIME DELAY INDICATOR - The present invention relates to an indicating device for use with medical injection devices for administering a drug into the body of a subject user wherein the indicating device is configured for indicating after administration that a dose of the drug actually has been administered and for maintaining this indication until lapse of a pre-defined time interval. The time delay indicator disclosed is based on a mechanical time delay device and includes a visual indicator that is controlled by the mechanical time delay device for signalling the status of the device during lapse of the pre-defined time interval. | 08-25-2011 |
| 20110177029 | O-LINKED GLYCOSYLATION USING N-ACETYLGLUCOSAMINYL TRANSFERASES - The present invention provides covalent conjugates between a polypeptide and a modifying group, such as a water-soluble polymer (e.g., PEG). The amino acid sequence of the polypeptide includes one or more O-linked glycosylation sequence, each being a substrate for a GIcNAc transferase. The modifying group is covalently linked to the polypeptide via a glycosyl-linking group interposed between and covalently linked to both the polypeptide and the modifying group. In one embodiment, a glucosamine linking group is directly attached to an amino acid residue of the O-linked glycosylation sequence. The invention further provides methods of making polypeptide conjugates. The present invention also provides non-naturally occurring polypeptides that include at least one O-linked linked glycosylation sequence of the invention, wherein each glycosylation sequence is a substrate for a GIcNAc transferase. The invention further provides pharmaceutical compositions that include a polypeptide conjugate of the invention. | 07-21-2011 |
| 20110166524 | Actuator System Comprising Lever Mechanism - The invention provides a pump assembly comprising an actuator lever, a supporting structure, a pump comprising a pump member moveable by actuation of the actuator lever, and an actuator for moving the actuator lever. A first stationary pivoting joint is formed between the actuator lever and the supporting structure, and a second floating pivoting joint is formed between the actuator lever and the pump member allowing the pump member to float relative to the actuator lever, the floating pivoting point providing a constant-length actuator arm defined between the first pivoting joint and the second pivoting joint. | 07-07-2011 |
| 20110166321 | DOUBLE-ACYLATED GLP-1 DERIVATIVES - The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 37 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at a position corresponding to position 26 of GLP-1(7-37), and a maximum of ten amino acid modifications as compared to GLP-1(7-37), wherein the first K residue is designated K | 07-07-2011 |
| 20110160670 | VENTED DRUG RESERVOIR UNIT - A reservoir unit is provided comprising a housing in which a reservoir with a transparent portion is arranged, the housing comprising a window allowing a portion of the reservoir to be inspected. The reservoir unit is adapted to be moved from a first “cold” condition to a second “warm” condition with no visible water condensing on the interior surface of the window portion. Further, the vent is adapted to provide pressure equalization between the interior of the housing and the exterior. In this way it is possible to perform visual inspection of the reservoir at all times without being confused by dew or condensed water drops, e.g. when a prefilled reservoir unit containing a drug which requires storage at a given low temperature, as is the case for insulin-containing drugs, is taken out in ambient temperature. | 06-30-2011 |
| 20110152185 | Pharmaceutical Compositions Comprising GLP-1 Peptides or Extendin-4 and a Basal Insulin Peptide - Pharmaceutical composition for parenteral administration comprising a basal insulin peptide and an insulinotropic GLP-1 peptide comprising at least 6 zinc atoms per 6 insulin molecules. | 06-23-2011 |
| 20110152183 | DERIVATISED HYBRID PEPTIDES OF AMYLIN AND SALMON CALCITONIN - Described are derivatives of hybrid peptides and pharmaceutical compositions comprising such, wherein said hybrid peptides comprise the C-terminal end of the human amylin peptide sequence, the middle portion of the salmon calcitonin peptide sequence and the N-terminal end of the human amylin peptide sequence, and wherein an albumin binding moiety is attached to the hybrid peptide, optionally via a linker. | 06-23-2011 |
| 20110144010 | Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier - The present invention relates to a solid or semi-solid pharmaceutical composition that includes a polypeptide drug, at least one polar organic solvent, at least one surfactant, at least one hydrophilic component and which composition is spontaneously dispersible. | 06-16-2011 |
| 20110137255 | Medical Skin Mountable Device - A medical device is provided comprising a transcutaneous device unit and a reservoir unit. The transcutaneous device unit comprises a transcutaneous device for transporting a fluid through a skin portion of a subject, and a mounting surface adapted for application to the skin of the subject. The reservoir unit comprises a reservoir adapted to contain a fluid drug, the reservoir comprising an outlet means allowing the transcutaneous device to be arranged in fluid communication with an interior of the reservoir, and an expelling assembly for expelling a fluid drug out of the reservoir and through the skin of the subject via the transcutaneous device. The transcutaneous device unit and the reservoir unit further comprise coupling means allowing the reservoir unit to be secured to the transcutaneous device unit in the situation of use. By this arrangement a two-unit system is provided which can be used in a convenient and cost-effective manner. | 06-09-2011 |
| 20110137011 | HYPERGLYCOSYLATED HUMAN COAGULATION FACTOR IX - The invention relates to hyperglycosylated human coagulation factor IX polypeptides, to processes for preparing said polypeptides, to pharmaceutical compositions comprising said polypeptides and to the use of the compounds for the treatment of diseases alleviated by human coagulation factor IX, in particular, but not exclusively hemophilia. | 06-09-2011 |
| 20110130402 | HETEROAROMATIC GLUCOKINASE ACTIVATORS - The present invention describes 2,3-di-substituted N-heteroaromatic propionamides, wherein the substitution at the 3-position is an optionally substituted phenyl ring and the substitution at the 2-position is an alkyl or cycloalkyl group; pharmaceutical compositions comprising the same; and, methods of using the same. The propionamides are glucokinase activators which increase insulin secretion for the treatment of type II diabetes. | 06-02-2011 |
| 20110124556 | Insulin and IGF-1 Receptor Agonists and Antagonists - Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics. | 05-26-2011 |
| 20110111460 | Method for Making Mature Insulin Polypeptides - The invention is related to a method for making human insulin analogues by culturing an fungi cell comprising a DNA vector encoding a precursor for human insulin analogue, wherein the said precursor comprises a connecting peptide flanked with cleavage sites at both junctions with the A- and the B-chain of the insulin peptide, respectively said cleavage sites being cleaved within the fungi cell allowing the cell to secrete high amount of correctly processed, mature two chain human insulin analogue to the culture media. | 05-12-2011 |
| 20110105394 | Amylin Derivatives - The present invention relates to novel amylin derivatives, pharmaceutical compositions containing such derivatives and to methods of treating diabetes and hyperglycaemia using the amylin derivatives of the invention. | 05-05-2011 |
| 20110098658 | INJECTION DEVICE HAVING MODE DEFINING ELEMENTS - An injection device ( | 04-28-2011 |
| 20110098440 | Insulin Analogues with an Acyl and Alkylene Glycol Moiety - An acylated insulin analogue wherein the insulin analogue comprises a lysine residue connected C-terminally to the A21 amino acid residue or a peptide residue of up to 4 amino acid residues comprising a lysine residue which peptide residue is connected C-terminally to the A21 amino acid residue, characterized in that an acyl moiety comprising an alkylene glycol moiety is attached to the lysine residue in the A22 position or attached to a lysine residue present in the peptide residue that is attached to the C terminal end of the A21 amino acid residue and wherein there is only one lysine (K, Lys) in the insulin analogue, can conveniently be administered pulmonary. | 04-28-2011 |
| 20110098439 | INSULINS WITH AN ACYL MOIETY COMPRISING REPEATING UNITS OF ALKYLENE GLYCOL CONTAINING AMINO ACIDS - Acylated insulins wherein an acyl moiety is attached to the parent insulin and wherein said acyl moiety comprises repeating units of alkylene glycol containing amino acids and wherein there is only one lysine residue (K & Lys) in the parent insulin have satisfactory properties when administered pulmonary. | 04-28-2011 |
| 20110098213 | Novel peptides for use in the treatment of obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity. | 04-28-2011 |
| 20110092419 | PROTEASE-STABILIZED INSULIN ANALOGUES - The present invention relates to novel insulin analogues comprising mutations at position A14 in the A chain and at positions B27, B28, B29 and B30 in the B chain and exhibiting resistance towards protease; a method for the preparation of such insulin analogues; insulin preparations containing the insulin analogues of the invention; and, a method of treating diabetes mellitus using these insulin analogues. | 04-21-2011 |
| 20110091475 | Anti-Human Interleukin-20 Antibodies - Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/AL20R2 and IL22R1/AL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treat-ing various diseases and disorders, including autoimmune or inflammatory diseases or disorders. | 04-21-2011 |
| 20110082079 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE - The invention relates to protracted Glucagon-Like Peptide-1 (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 derivative of the invention comprises a modified GLP-1(7-37) sequence having a total of 2-12 amino acid modifications, including Glu22 and Arg26, and being derivatised with an albumin binding residue or pegylated in position 18, 20, 23, 30, 31, 34, 36, 37, or 39. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and/or a high affinity of binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration. | 04-07-2011 |
| 20110077963 | SYSTEM AND METHOD FOR ASSISTING IN THE HOME TREATMENT OF A MEDICAL CONDITION - An interactive home treatment system and method is disclosed. Patient data is collected via a handheld device and stored in a database. The data may be related to self-treatments, symptoms, or patient behavior. The data are analyzed with an analytic tool and the analysis is used to generate a message that is transmitted to a treating health care professional or to the patient, or both. A set of predetermined rules may be applied to the data. The rules may be modified by the treating health care professional, the patient, or both. The handheld device, the database, and the analytic tool may be web-enabled to facilitate communication from virtually anywhere. | 03-31-2011 |
| 20110077234 | Urea Glucokinase Activators - The invention provides a compound of general formula (I) | 03-31-2011 |
| 20110064719 | HYDROPHOBIC INTERACTION CHROMATOGRAPHY PURIFICATION OF FACTOR VII POLYPEPTIDES - The invention described herein provides new methods of preparing purified Factor VII polypeptide drug substances in large quantities (industrial scale levels) that are associated with reduced content of product-related impurities (e.g., late eluting peaks) and/or that exhibit a relatively uniform glycosylation pattern. | 03-17-2011 |
| 20110060289 | INTEGRATED PACKAGE - The present invention generally relates to skin-mountable devices. A device in accordance with the invention comprises a first skin-mountable unit having a mounting surface comprising adhesive means for adhering the unit to the skin of a subject, and a second handling unit releasably attached to the skin-mountable unit. The handling unit comprises an interior space at least partially accommodating the skin-mountable unit and has an opening through which the skin-mountable member can be moved when detached from the handling unit, the handling unit having a portion surrounding the opening. The device further comprises a seal member releasably attached to the circumferential portion, thereby providing a closed space for the skin-mountable unit. In this way a device is provided allowing for easy handling as a user can use the handling unit to grip and handle the combined device during operation thereof, just as the second unit can be designed and optimized for ease of use during manipulation of the skin-mountable unit. | 03-10-2011 |
| 20110060019 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS - This invention relates to compounds of formula (I) | 03-10-2011 |
| 20110059894 | Factor VII Polypeptides for Preventing Formation of Inhibitors in Subjects with Haemophilia - The invention provides a method for preventing formation of inhibitors to blood coagulation factor VIII or factor IX in a subject having haemophilia, the method comprising administering (via intravenous, subcutaneous, intradermal, or intramuscular routes) to a previously untreated subject an effective dosage of factor VIIa or a factor VII-related polypeptide. | 03-10-2011 |
| 20110053839 | GLP-1 Derivatives II - The present invention relates to a derivative of GLP-1(7-C), wherein C is 35 or 36 which derivative has just one lipophilic substituent which is attached to the C-terminal amino acid residue. | 03-03-2011 |
| 20110046567 | INJECTION DEVICE FOR PERFORMING MEDICAL INJECTIONS - The present invention concerns a prefilled injection device having a container and a dose setting mechanism encapsulated inside the housing. The injection device incorporates an axial variable connection such that the distance between the distal end of the piston rod means and the plunger is minimized preferably to zero. | 02-24-2011 |
| 20110046566 | Medical Delivery System Comprising Locking Ring with L-Shaped Grooves - A medical delivery system ( | 02-24-2011 |
| 20110046565 | DEVICE FOR INJECTING APPORTIONED DOSES OF LIQUID DRUG - A mechanical injection device ( | 02-24-2011 |
| 20110046049 | Soluble, Stable Insulin-Containing Formulations with a Protamine Salt - The present invention relates to pharmaceutical formulations comprising insulin, an insulin analog, an insulin derivative, or a combination of any of the foregoing, and a salt of protamine, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the insulin peptide(s) contained in such formulations is indicated. The present invention further relates to methods for increasing the stability and/or solubility of insulin in insulin-containing formulations at a pH less than 7.0 by adding a salt of protamine to the insulin-containing formulations. | 02-24-2011 |
| 20110039841 | Novel compounds, their preparation and use - Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ subtype. | 02-17-2011 |
| 20110039769 | INSULIN ALBUMIN CONJUGATES - Insulin albumin conjugates consisting of an insulin analogue, a bifunctional linker and albumin can efficiently be used to treat diabetic patients. | 02-17-2011 |
| 20110034878 | DEVICE FOR INJECTING APPORTIONED DOSES OF LIQUID DRUG - A mechanical injection device ( | 02-10-2011 |
| 20110034870 | Drug Mixing and Infusion Device - A drug mixing device for mixing a lyophilized drug with a liquid, thereby forming a liquid drug and for infusion of the liquid drug. The device comprises a first ( | 02-10-2011 |
| 20110028391 | Use of GLP-1 Peptides - GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety. | 02-03-2011 |
| 20110021988 | Safety Needle Assembly - The invention relates to a safety needle assembly for injecting a fluid into a human body comprising a cylindrical housing with a bottom surface supporting a needle cannula and a shield telescopically movable relative to the housing. A spring located within the housing urges the shield in a distal needle covering direction and a locking member also provided inside the housing moves simultaneously with the shield during injection and automatically locks the shield in a position where the sharp end of the needle cannula is concealed thereby irreversible immobilizing the safety needle assembly. | 01-27-2011 |
| 20110020297 | DNER-MEDIATED CELL PURIFICATION OF PANCREATIC ENDOCRINE PRE-PROGENITOR CELLS AND THEIR PROGENY - The invention relates to a method of identifying and obtaining a culture cells comprising cells selected from the group consisting of endocrine pre-progenitor cells, endocrine progenitor cells, early endocrine cells, and/or fully differentiated endocrine cells. Also contemplated is a method of expanding the number of such cells as well as sorting such cells. In some aspects the invention further relates to a selective cell surface marker, DNER, that permits the selection of a unique subset of cells with endocrine pre-progenitor, endocrine progenitor, early endocrine, and/or fully differentiated endocrine phenotype. In some aspects the selective cell surface marker is selected from the group consisting of DNER, DISP2, SEZ6L2, LRP1 1 and SLC30A8. Furthermore, the invention relates to isolated cells selected from such cells and compositions thereof. | 01-27-2011 |
| 20110015270 | Novel NIDDM Regimen - The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone. | 01-20-2011 |
| 20110014160 | DDR1-Mediated Cell Purification of Pancreatic Endocrine Cells Through Their Progenitors - The invention relates to a method of identifying, obtaining and/or quantifying a culture of pancreatic cells selected from the group consisting of ductal/endocrine progenitor cells, endocrine progenitor cells, early endocrine cells, and fully differentiated endocrine cells. Also contemplated is a method of expanding the numbers of such cells as well as sorting such cells. The invention further relates to a selective cell surface marker, DDR1, that permits the selection of a unique subset of cells with pancreatic endocrine progenitor phenotype. Furthermore, the invention relates to isolated cells selected from such cells and compositions thereof. | 01-20-2011 |
| 20110009314 | Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof - The present invention is related to fast acting single-chain insulin comprising a modified B-chain and the A-chain of human insulin or an analogue thereof connected by a connecting peptide wherein one or more of the amino acid residues in position B25, B26 or B27 in the human B-chain are Glu or Asp or are deleted and/or B28 is Glu, Asp, Lys or is deleted, and the amino acid residue in position B10 in the human insulin B-chain is Gln, Ala, Val, Thr or Ser. The invention is also related to pharmaceutical compositions being a mixture of the rapid acting single-chain insulin and the protracted acylated insulin. | 01-13-2011 |
| 20110008206 | Non-Porous Material as Sterilization Barrier - The invention provides a device comprising a sealed interior portion with at least one opening covered by a sterilization barrier formed from a non-porous material allowing a sterilization gas to penetrate but prevents germs from penetrating. The size and configuration of the at least one sterilization barrier formed from a non-porous material are adapted to allow at least 50% of the sterilization gas, that would pass between a sterilization gas-containing exterior and the sealed interior portion when a pressure difference is created there between, to pass through the non-porous material. | 01-13-2011 |
| 20110003744 | Glycopegylated Erythropoietin Formulations - The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates. | 01-06-2011 |
| 20100330645 | ONE POT DESIALYLATION AND GLYCOPEGYLATION OF THERAPEUTIC PEPTIDES - The present invention provides conjugates between peptides and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention. | 12-30-2010 |
| 20100330060 | GLYCOPEGYLATED FACTOR IX - The present invention provides conjugates between Factor IX and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates. | 12-30-2010 |
| 20100324499 | Injection Device - An injection device with a travelling clutch which can be shifted between two different positions by the activation of an injection button. In the first position, the injection button and the driver is allowed to rotate relatively to the piston rod, which is blocked from rotation by the clicker element. In the second position, the drive sleeve and the injection button is axially movable while the piston rod is allowed to rotate. | 12-23-2010 |
| 20100324498 | Medical delivery system comprising a container and a dosing assembly with radially moving fastening means - A medical delivery system wherein one of a container and a dosing assembly comprises a first fastening means ( | 12-23-2010 |
| 20100322940 | IN VITRO MODIFICATION OF GLYCOSYLATION PATTERNS OF RECOMBINANT GLYCOPEPTIDES - This invention provides methods for modifying glycosylation patterns of glycopeptides, including recombinantly produced glycopeptides. Also provided are glycopeptide compositions in which the glycopeptides have a uniform glycosylation pattern. | 12-23-2010 |
| 20100318060 | Injection Device With Rotatable Dose Setting - An injection device comprising a housing and a dose setting mechanism including a dose setting element. Contrary to prior art injection devices, the dose setting element can only be set at a few different dose settings. This is established by forming the dose setting element as a rotatable dish concealed within the housing and having a number of projections projecting outside the boundaries of the housing through a slot in the housing. A dose is set by activating a projection which in addition provides the user with a tactile guidance. Usually one projection is provided for one dose setting limiting the number of doses to be set to the number of projections. | 12-16-2010 |
| 20100317057 | SEMI-RECOMBINANT PREPARATION OF GLP-1 ANALOGUES - A semi-recombinant method for the production of GLP-1 analogues and derivatives with non-proteogenic amino acids in the N-terminal part combining the use of recombinant expression techniques and chemical peptide synthesis. | 12-16-2010 |
| 20100305032 | Novel GLP-1 Derivatives - Novel polypeptide derivatives having protracted profile of action. | 12-02-2010 |
| 20100298213 | Pharmaceutically Active Insulin Receptor-Modulating Molecules - The invention described herein provides novel pharmaceutically active molecules (including novel peptide derivatives and peptides) that bind to an insulin receptor; compositions comprising such molecules; methods of modulating insulin receptor activity comprising the delivery of such molecules and related insulin-binding molecules (e.g., in the context of treating and/or preventing insulin receptor-related diseases such as diabetes); nucleic acids encoding such peptides; vectors and host cells comprising such nucleic acids; and methods of producing such molecules and compositions. | 11-25-2010 |
| 20100292444 | Novel Prolactin Compounds - The present invention relates to prolactin analogues, which analogues have increased resistance to deamidation. | 11-18-2010 |
| 20100292133 | TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE - The invention relates to truncated GLP-1 analogues, in particular a GLP-1 analogue which is a modified GLP-1(7-35) (SEQ ID No 1) having: i) a total of 2, 3, 4, 5 6, 7, 8, or 9 amino acid substitutions as compared to GLP-1(7-35), including a) a Glu residue at a position equivalent to position 22 of GLP-1(7-35), and b) an Arg residue at a position equivalent to position 26 of GLP-1(7-35); as well as derivatives thereof, and therapeutic uses and compositions. These analogues and derivatives are highly potent, have a good binding affinity to the GLP-1 receptor, also to the extracellular domain of the GLP-1 receptor, which is of potential relevance achieving long-acting, stable GLP-1 compounds with a potential for once weekly administration. | 11-18-2010 |
| 20100291110 | Compositions and Methods for Regulating NK Cell Activity - The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects. | 11-18-2010 |
| 20100280460 | Automatic Injection Device - An automatic injection device ( | 11-04-2010 |
| 20100280329 | ESTIMATING A NUTRITIONAL PARAMETER FOR ASSISTING INSULIN ADMINISTRATION - A device for estimating a nutritional parameter of a meal consumed by an individual is disclosed. The apparatus comprises processing means adapted to obtain input values of at least a physiological parameter of the user measured prior to and after intake of a meal by the user, and of at least a dose of medication administered to the user. Based on the input values the apparitus is adapted to determine from at least the obtained input values, an estimate of a nutritional parameter of the meal and to generate an output to a user indicative of the determined estimate. | 11-04-2010 |
| 20100272718 | Antibodies Against Human NKG2D and Uses Thereof - The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient. Preferred antibodies include human monoclonal antibodies MS and 21F2. As described herein, other antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules, can be designed or derived from such antibodies. | 10-28-2010 |
| 20100261637 | PEPTIDES DERIVATIZED WITH A-B-C-D- AND THEIR THERAPEUTICAL USE - The invention relates to protracted peptide derivatives such as Glucagon-Like Peptide-1 (GLP-1), exendin-4, and analogues thereof, as well as therapeutic uses thereof. The peptide derivative of the invention comprises a peptide wherein at least one amino acid residue is derivatized with A-B-C-, or A-B-C-D-. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, have a low ratio of binding affinity to the GLP-1 receptor in the presence of high/low albumin concentrations, have long half-lives, and have a high affinity of binding to albumin, all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration. | 10-14-2010 |
| 20100250697 | Portable Device And Method Of Communicating Medical Data Information - A portable medical device for communication of medical data information has a medical device part that includes a first processor and first storage means, and means for executing one or more medical related functions, a communication device part comprising a second processor, second storage means, and communication means. The medical device part and the communication device part are connected allowing for exchange of data information according to a predetermined protocol. The exchange of communication may be under the control of the medical device part, but the functionalities of each device part otherwise is separated providing for easy interchangeability of the communication device part or the medical device part. Also disclosed is a method for communication of medical data information. | 09-30-2010 |
| 20100249029 | Peptides with high affinity for the prolactin receptor - The invention relates to variants of prolactin, which variants have high affinity for the prolactin receptor. | 09-30-2010 |
| 20100247526 | Anti-NKG2A Antibodies and Uses Thereof - Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described. | 09-30-2010 |
| 20100241066 | Mechanism for Injection Device - A pressurised injection device comprises a mechanical loading mechanism comprising a double set of rackets ( | 09-23-2010 |
| 20100240587 | STABLE FORMULATIONS OF AMYLIN AND ITS ANALOGUES - The invention relates to a soluble pharmaceutical composition for parenteral administration, which comprises an amylin peptide and an anionic surfactant, and methods for treatment of hyperglycemia. | 09-23-2010 |
| 20100234811 | SHIELDABLE NEEDLE ASSEMBLY WITH BIASED SAFETY SHIELD - A needle assembly for an injection device comprising a needle cannula which is mounted in a hub connectable to an injection device, and a biasing shield which is telescopically guided relative to the hub between a position in which the needle cannula is covered and a position in which at least the sharp end of the needle cannula is exposed, such that an injection can be performed without visual contact with the needle cannula. Further releasable locking means is provided such that the user can lock or unlock the shield to perform the telescopically movement. In order to release the shield, the injection device itself can be utilized as the key for unlocking. | 09-16-2010 |
| 20100234299 | STABLE FORMULATION OF MODIFIED GLP-1 - Pharmaceutical formulations of GLP-1 compounds and methods for preparation thereof. | 09-16-2010 |
| 20100227796 | Insulin Derivatives - The present invention is related to insulin derivatives having a side chain attached either to the α-amino group of the N-terminal amino acid residue of B chain or to an ε-amino group of a Lys residue present in the B chain of the parent insulin molecule via an amide bond which side chain comprises one or more residues of ethylenglycol, propyleneglycol and/or butyleneglycol containing independently at each termini a group selected from —NH | 09-09-2010 |
| 20100222277 | Regulation of Food Preference Using GLP-1 Agonists - GLP-1 agonists selectively decrease the amount of food intake, wherein the food has a high glycemic index or wherein the amount of mono- and di-saccharides together constitute a large proportion of the total amount of carbohydrates. | 09-02-2010 |
| 20100222269 | IMPROVED DERIVATIVES OF AMYLIN - The invention relates to derivatives of human amylin or analogues thereof which bind to the amylin receptor and are linked to an albumin binding compound, pharmaceutical compositions comprising these derivatives and methods for obtaining such. | 09-02-2010 |
| 20100222251 | MIXTURE COMPRISING AN AMYLIN PEPTIDE AND A PROTRACTED INSULIN - The invention relates to a soluble pharmaceutical composition for parenteral administration, which comprises an amylin peptide and a protracted insulin peptide. | 09-02-2010 |
| 20100216715 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use - The present invention relates to Fibroblast Growth Factor 21 (FGF21), more in particular to derivatives of FGF21 compounds having an albumin binder of the formula A-B-C-D-E- covalently attached. The invention also relates to novel FGF21 analogues, as well as to the pharmaceutical use of these FGF21 derivatives and analogues, in particular for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). The derivatives of the invention are protracted, e.g. capable of maintaining a low blood glucose level for a longer period of time, capable of increasing the in vivo half-life of FGF21, and/or result in a lower clearance of FGF21. The derivatives of the invention are preferably furthermore of an improved oxidative stability. | 08-26-2010 |
| 20100216691 | Protease Stabilized, Pegylated Insulin Analogues - Novel PEGylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H. The PEGylation is at B29K. | 08-26-2010 |
| 20100216690 | Pegylated Single-Chain Insulin - The present invention is related to a single-chain insulin comprising the B- and the A-chain of human insulin or analogues thereof connected by a connecting peptide having from 3-35 amino acid residues, wherein the single-chain insulin comprises at least one PEG group attached to at least one lysine residue in the single-chain insulin molecule and/or to the B1 N terminal amino acid residue. The PEGylated single-chain insulins may comprise up to 4 PEG groups which may be the same or different. | 08-26-2010 |
| 20100205001 | SYSTEM AND METHOD FOR ASSISTING IN THE HOME TREATMENT OF A MEDICAL CONDITION - An interactive home treatment system and method is disclosed. Patient data is collected via a handheld device and stored in a database. The data may be related to self-treatments, symptoms, or patient behavior. The data are analyzed with an analytic tool and the analysis is used to generate a message that is transmitted to a treating health care professional or to the patient, or both. A set of predetermined rules may be applied to the data. The rules may be modified by the treating health care professional, the patient, or both. The handheld device, the database, and the analytic tool may be web-enabled to facilitate communication from virtually anywhere. | 08-12-2010 |
| 20100204288 | Heteroaryl-Ureas and Their Use as Glucokinase Activators - This invention relates to compounds of formula (I) | 08-12-2010 |
| 20100196477 | Dry Mouldable drug formulation - Solid pharmaceutical compositions and methods of making and administering for parenteral injection comprising a binder and at least one therapeutic agent. The pharmaceutical composition has the strength to be injected directly with the need of using cannulas or the like. | 08-05-2010 |
| 20100194537 | CONTACT FREE READING OF RESERVOIR IDENTIFICATION CODES - The present invention relates to a medicament reservoir adapted to contain a medicament, the reservoir further being adapted to be received by an associated medical delivery device. The reservoir according to the present invention comprises an identification code comprising a plurality of electrode arrays arranged on an exterior surface part of the reservoir. The code comprises a first, a second and a third array of discrete electrodes adapted to electrically couple to transmitter electrodes and receiver electrodes in the reader of the associated medical delivery device. One of the arrays may be provided to obtain a measure of angular alignment between identification code and reader of the medical delivery device. | 08-05-2010 |
| 20100190715 | Stable Formulations of Peptides - Method for increasing the shelf-life of a pharmaceutical formulation comprising a glucagon-like peptide. | 07-29-2010 |
| 20100190706 | Stable Non-Aqueous Pharmaceutical Compositions - The present invention relates to shelf stable non-aqueous pharmaceutical compositions, and to the use thereof in methods of treating diabetes and hyperglycaemia, comprising insulinotropic peptide and semi-polar protic organic solvent. | 07-29-2010 |
| 20100185152 | Dosing Operation In A Medical Device - This invention relates to a method of controlling a dosing operation where a piston in a medical device is moved to a desired position, the dosing operation applies a motor to provide a force from the piston to expel a dose of a liquid medicament, said method comprising the steps of: moving the piston, at a first fixed speed, to a first position of the movement, moving the piston, at a decreasing speed, from said first position to a second position of the movement, and moving the piston, at a second fixed speed, from said second position to the desired position of the movement. The method further comprises the step of letting a fixed waiting time pass, when the piston has reached the desired position. This enables for a precise movement and stop of the piston leading to a precise dose, minimized post dripping and to that only a fixed and short waiting time need to go before a user can withdraw an injection needle of the medical device from his skin. | 07-22-2010 |
| 20100184690 | Combined Use Of A GLP-1 Compound And A Modulator Of Diabetic Late Complications - Methods and uses for treatment of diabetic late complications comprising administration of a GLP-1 compound and a modulator of diabetic complications. | 07-22-2010 |
| 20100184687 | Purification of Glucagon-Like Peptides - Method for purifying a glucagon-like peptide by reversed phase high performance liquid chromatography. | 07-22-2010 |
| 20100184641 | Novel Plasma Protein Affinity Tags - Method for increasing half-life of therapeutic agents in plasma and novel polypeptide derivatives. | 07-22-2010 |
| 20100184133 | Method for making maturated insulin polypeptides - The invention is related to a method for making mature human insulin or an analogue thereof by culturing a fungi cell comprising a DNA sequence encoding a precursor for human insulin or an analogue of human insulin which precursor comprises the B-chain of human insulin or an analogue thereof, the A-chain of human insulin or an analogue thereof and a C-peptide linking the B-chain and the A-chain together thereof, wherein the C-peptide comprises at least one Kex2 cleavage site and an amino acid sequence attached at one end to the C-terminal amino acid residue in the B-chain and at the other end to the Kex2 site which amino acid sequence will facilitate a more efficient Kex2 cleavage within the fungi cell. The C-terminal extension of the B-chain may furthermore be capable of subsequently being cleaved off from the C-terminal amino acid residue in the B-chain by means of a carboxypeptidase activity either within the fungi cell or subsequently in the culture medium. | 07-22-2010 |
| 20100179485 | INJECTION DEVICE - The invention concerns an injection device for apportioning set doses of a drug from a reservoir to a subject. The injection device comprises a housing having an interior thread formed as an outwardly pointing thread carried on an upstanding tower centrally located in the pen shaped device. This outwardly pointing thread forms a first thread connection with the interior thread of the rotatable scale drum. The injection device further comprises a driver for moving the piston rod forward when moved axially. The driver operates the piston rod through a second thread connection having a pitch different than the first thread connection. | 07-15-2010 |
| 20100174059 | PROCESS FOR THE PRODUCTION OF NUCLEOTIDE SUGARS - The current invention provides methods (e.g., large-scale processes) for the production of nucleotide sugars, which are modified with a polymeric modifying group, such as poly(alkylene oxide) moieties (e.g., poly(ethylene glycol) or poly(propylene glycol)) moieties. A typical process of the invention includes anion exchange chromatography followed by an ultrafiltration procedure, such as tangential flow filtration. The process of the invention provides modified nucleotide sugars in unexpectedly high purity and high overall yields. | 07-08-2010 |
| 20100173844 | Stable Formulations of Peptides - Stable pharmaceutical composition comprising insulinotropic peptide. | 07-08-2010 |
| 20100173835 | Peptides for Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity. | 07-08-2010 |
| 20100173357 | METHOD OF MAKING ACTIVATED CARBOXYPEPTIDASES - The invention is related to a method for making an activated carboxypeptidase in a fungi cell comprising introducing a DNA sequence encoding a proform of the carboxypeptidase wherein a Kex2 site has been introduced in the prosequence of the carboxypeptidase, culturing the fungi cell under conditions suitable for expression of the procarboxypeptidase and cleaving off the prosequence within the cell to liberate the free active form of the carboxypeptidase. The invention is also related to methods for making mature human insulin and human insulin analogues by use of the activated carboxypeptidase enzyme. | 07-08-2010 |
| 20100167990 | Pharmaceutical Formulations Comprising an Insulin Derivative - The invention concerns a soluble pharmaceutical formulation comprising an insulin derivative wherein the formulation further comprises more than 4 zinc atoms per 6 molecules of the insulin derivative, and a citric acid monohydrate and/or a histidine compound used in an amount sufficient to increase the tendency of the insulin derivative to self-associate into dodecamers. The invention further comprises a process for preparing the soluble pharmaceutical formulation. | 07-01-2010 |
| 20100145282 | INJECTION BUTTON - A push button connection for an injection device comprising a push button ( | 06-10-2010 |
| 20100145262 | SAFETY SYSTEM FOR INSULIN DELIVERY ADVISORY ALGORITHMS - A closed loop control system for a medical drug delivery device logs historical data such as drug delivered and corresponding physiological parameters such as blood glucose level. On the basis of the logged historical data, the system calculates an estimated event forecast on which basis the system further calculates the necessary, prudent future drug delivery profile in order to counter delay in the closed loop. The estimated event forecast is presented to the user, the user is thereby given the possibility to accept, reject or adjust the event forecast and the corresponding drug delivery profile. Dynamic and adaptive safety limits to the drug delivery and the physiological parameter can be set by the user and will dynamically follow the drug delivery profile and the event forecast and will further optimize based on the learned behavioural pattern of the user. The user can set the safety level as a percentage of deviation to the drug delivery profile. | 06-10-2010 |
| 20100137830 | MEDICATION DELIVERY DEVICE COMPRISING A PLURALITY OF RESERVOIRS - The present invention relates to a medication delivery device for delivering a set dose of medicament, the medication delivery device comprising pump means having first and second pump chambers. The first pump chamber is adapted to transfer medicament from a first collapsible reservoir to an outlet arrangement, said outlet arrangement being in fluidic communication with an associated hypodermic needle. The second pump chamber is adapted to transfer substance from a second reservoir to the outlet arrangement, wherein the first pump chamber is adapted to deliver the set dose of medicament during one or more pump strokes, the stroke volume(s) of said one or more pump strokes being variable. | 06-03-2010 |
| 20100133099 | ELECTRONIC DEVICE ASSEMBLY WITH SAFETY ELECTRIC CONNECTOR - The application provides an assembly comprising a housing ( | 06-03-2010 |
| 20100120094 | FACTOR VIII POLYPEPTIDE TITERS IN CELL CULTURES - The invention relates to a method for the production of a Factor VIII polypeptide, the method comprising the steps of a) culturing a mammalian cell expressing a Factor VIII polypeptide under conditions for expression of said Factor VIII polypeptide, said culturing conditions involving a cell culture medium comprising a C2-domain ligand, and b) isolating the expressed Factor VIII polypeptide from the mammalian cell by suitable means. | 05-13-2010 |
| 20100114035 | BACK NEEDLE - A needle assembly for an injection device comprising a needle cannula which is mounted in a hub connectable to an injection device, and which needle assembly comprises a back needle. Further the needle assembly is provided with means which, when activated, prevents a user from physically contacting the back needle. | 05-06-2010 |
| 20100114025 | INJECTION DEVICE COMPRISING A LOCKING NUT - The invention relates to an injection device for injecting a dose of drug. The injection device comprises a housing, a dose setting mechanism being operable to set a desired dose, an injection mechanism comprising a piston rod ( | 05-06-2010 |
| 20100113747 | Coupling of Antibody Polypeptides at the C-Terminus - The present invention relates to a process for dimerization of antibody fragments, antibody fragment dimers, pharmaceutical compositions comprising antibody fragment dimers as well as their use in medicaments for therapeutic applications. The methods described can advantageously be used for producing bispecific antibodies and/or bispecific fragments thereof. | 05-06-2010 |
| 20100113743 | GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA - The present invention provides conjugates between Factor VII or Factor VIIa peptides and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention. | 05-06-2010 |
| 20100113363 | Use of GLP-1 Peptides - GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety. | 05-06-2010 |
| 20100106100 | MEDICAL DELIVERY SYSTEM HAVING CONTAINER RECOGNITION AND CONTAINER FOR USE WITH THE MEDICAL DELIVERY SYSTEM - A medical delivery system comprising a container and a dosing assembly where the container is fastenable to the dosing assembly. When the container is secured to the dosing assembly, a recognition feature on the container is adapted to co-operate with a variable resistor disposed in the dosing assembly to thereby facilitate an identification of the specific type of container which is secured to the dosing assembly. Furthermore, the present invention relates to a container and a dosing assembly suitable for use in the medical delivery system according to the present invention. | 04-29-2010 |
| 20100106099 | Syringe Device - A medical delivery system comprising a container and a coupling mechanism movable between a coupling position wherein distal movement of a drive mechanism is transferred to an actuator, and a non-coupling position wherein distal movement is not transferred to the actuator. Moreover the present invention relates to a dosing assembly for use in the medical delivery system and a container for use in the medical delivery system. Finally, the present invention relates to medical delivery system comprising a dosing assembly having means for preventing a drive stem of the dosing assembly from being moved in a distal direction. | 04-29-2010 |
| 20100105863 | Method For Producing Acylated Peptides - The present invention provides a method for acylating one or more amino groups of a peptide where the acylation reaction is to be performed in an aqueous mixture containing less than 10% w/w aprotic polar solvent. | 04-29-2010 |
| 20100105603 | Methods and Preparations For Curing Clinically Ill Patients - This invention relates to a life saving medicament for critically ill patients and a method of treatment. The composition is a pharmaceutically effective amount of a blood glucose regulator which is used to control the blood glucose level. | 04-29-2010 |
| 20100100048 | Medical Skin Mountable Device - A medical device is provided comprising a transcutaneous device unit and a reservoir unit. The transcutaneous device unit comprises a transcutaneous device for transporting a fluid through a skin portion of a subject, and a mounting surface adapted for application to the skin of the subject. The reservoir unit comprises a reservoir adapted to contain a fluid drug, the reservoir comprising an outlet means allowing the transcutaneous device to be arranged in fluid communication with an interior of the reservoir, and an expelling assembly for expelling a fluid drug out of the reservoir and through the skin of the subject via the transcutaneous device. The transcutaneous device unit and the reservoir unit further comprise coupling means allowing the reservoir unit to be secured to the transcutaneous device unit in the situation of use. By this arrangement a two-unit system is provided which can be used in a convenient and cost-effective manner. | 04-22-2010 |
| 20100100047 | MEDICATION DELIVERY DEVICE WITH PRE-SET BOLUS PUMP - The present invention relates to a handheld medication delivery device comprising first and second mutually displaceable housing parts ( | 04-22-2010 |
| 20100099620 | Protracted GLP-1 Compositions - Thixotropic compositions containing GLP-1 compounds have protracted action. | 04-22-2010 |
| 20100099142 | Processing of Peptides and Proteins - The invention provides novel methionine aminopeptidase enzymes and their use. | 04-22-2010 |
| 20100092493 | Modulation of Complement System Activation for Treatment of Bleeding-Related Inflammation - This invention provides, inter alia, methods and compositions for treating, reducing the incidence of, reducing the severity of, or delaying onset or advancement, of synovitis and/or bleeding-associated inflammation in a subject in need thereof. The compositions comprise, and methods make use of, an effective amount of an agent, which abrogates or diminishes activation of the C5aR complement pathway in said subject, and optionally other therapeutic agents including a coagulation factor, other hemostatic factor, and/or second anti-inflammatory agent. | 04-15-2010 |
| 20100081791 | GLYCOPEGYLATED FACTOR IX - The present invention provides conjugates between Factor IX and PEG moieties. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates. | 04-01-2010 |
| 20100076395 | ELECTRICALLY CONDUCTIVE CARTRIDGE OR CARTRIDGE HOLDER - The present invention relates to a cartridge or a cartridge holder adapted to be used in connection with handheld medication delivery devices. In particular, the present invention relates to intermediately positioned cartridges or cartridge holders providing at least one electrical connection between electronics of a medication delivery device and an injection needle attached to the medication delivery device. The electrical connection(s) between the electronics and the injection needle may be of galvanic or capacitive nature, the latter being provided via medicament contained in the cartridge. | 03-25-2010 |
| 20100069890 | USER INTERFACE FOR MEDICAL SYSTEM COMPRISING DIARY FUNCTION WITH TIME CHANGE FEATURE - The invention provides a device for displaying information, comprising display means adapted to graphically display information as a function of time for a given period of time, and input means for changing the time from a first time setting to a second time setting, thereby generating an end of time value for the first setting and a start of time value for the second time setting. The display means is controlled to display a first and a second view, the first view displaying, for the given period of time, information corresponding to the first time setting until the end of time value, the second view displaying, for the given period of time, information corresponding to the second time setting from the start of time value. In the first view the period between the end of time value and the end of the given period is indicated as not comprising information as a function of time, and in the second view the period between the beginning of the given period and the start of time value is indicated as not comprising information as a function of time. By this arrangement a user interface is provided reducing the likelihood that graphically displayed information is misinterpreted in case of a time change event. | 03-18-2010 |
| 20100069605 | PEPTIDE EXTENDED INSULINS - Insulins to which there is connected an amino acid oligomer have satisfactory properties. | 03-18-2010 |
| 20100063448 | PUMP ASSEMBLY COMPRISING ACTUATOR SYSTEM - The invention provides a pump assembly comprising an actuator lever, an actuator for moving the actuator lever, a supporting structure, a pump comprising a pump member moveable by actuation of the actuator lever, a first pivoting joint formed between the actuator lever and the supporting structure, and a second pivoting joint formed between the actuator and the supporting structure. The actuator lever and the actuator are coupled to each other by a coupling joint arranged between the first and the second pivoting joint in such a way that rotation of the actuator in a first direction causes the actuator lever to rotate in an opposite second direction. By providing an actuator system comprising two actuator elements linked to each other by a coupling joint ensuring counter rotation of the two members, a system is provided which can be made less susceptible to the influence of acceleration. | 03-11-2010 |
| 20100063438 | Fluid Delivery Device With Integrated Monitoring Of Physiological Characteristics - The present application relates to a drug delivery device ( | 03-11-2010 |
| 20100060464 | Medication Delivery Device With Reminder Unit - The present invention relates to a medication delivery device comprising a reminder unit for reminding an individual having a medical diseases to take a medicament. The reminder unit comprises means for providing a reminder signal to the individual having the medical disease, the reminder signal being triggered by data associated with a previously occurred event, the associated data being stored in a storage means. Alternatively, the reminder signal may be triggered by a position signal generated by position determining means adapted to determine the position of the medication delivery device. | 03-11-2010 |
| 20100056764 | Antibodies against human NKG2D and uses thereof - The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient. Preferred antibodies include human monoclonal antibodies MS and 21F2. As described herein, other antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules, can be designed or derived from such antibodies. | 03-04-2010 |
| 20100056451 | Stabilized Pharmaceutical Peptide Compositions - Method for increasing the shelf-life of a pharmaceutical composition for parenteral administration comprising a glucagon-like peptide which is prepared from a peptide product that has been subjected to treatment at a pH above neutral pH. | 03-04-2010 |
| 20100056433 | Novel Peptides for Use in the Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity. | 03-04-2010 |
| 20100055738 | Method for Making Acylated Polypeptides - The present invention related to a method of producing polypeptides in transformed host cells by expressing a precursor molecule of the desired polypeptide which are to be acylated in a subsequent in vitro step. The invention is also related to DNA-sequences, vectors and transformed host cells for use in the claimed method. Further, the present invention is related to certain precursors of the desired polypeptides and certain acylation methods. The invention provides a method for making polypeptides being preferentially acylated in certain lysine ε-amino groups. | 03-04-2010 |
| 20100048456 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS - The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide. | 02-25-2010 |
| 20100042054 | Medical Delivery System Comprising a Coding Mechanism Between Dosing Assembly and Medicament Container - A medical delivery system comprising a container for accommodation of a medicament and a dosing assembly adapted to be fastened to the container. The medical delivery system comprises a coding mechanism ( | 02-18-2010 |
| 20100041711 | Urea Glucokinase Activators - This application relates to novel urea glucokinase activators and use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes. Further encompassed is a pharmaceutical composition comprising a compound according to the invention and a process for preparing such. | 02-18-2010 |
| 20100035814 | N-Terminal Pegylated Prolactin Receptor Molecules - The invention is concerned with N-terminally pegylated polypeptides capable of binding to the prolactin receptor. Such polypeptides may for instance be N-terminally pegylated antagonists of the prolactin receptor, such as for instance prolactin variants. | 02-11-2010 |
| 20100035299 | METHODS FOR THE PURIFICATION OF POLYPEPTIDE CONJUGATES - The present invention provides processes for the manufacturing of polypeptide conjugates. In particular, the invention provides methods for the purification of polypeptide conjugates, which include at least one polymeric modifying groups, such as a poly(alkylene oxide) moiety. Exemplary poly(alkylene oxide) moieties include poly(ethylene glycol) (PEG) and poly(propylene glycol). In an exemplary process, hydrophobic interaction chromatography (HIC) is used to resolve different glycoforms of glycoPEGylated polypeptides. | 02-11-2010 |
| 20100030158 | Medical Delivery System with Flexible Blocking Element - A container suitable for use in said medical delivery system and a medical delivery system having a container and a dosing assembly, where the container is fastenable to the dosing assembly by a movement comprising a translatory movement followed by a rotational movement. One of the container and the dosing assembly comprises one or more blocking elements movable between a blocking position and a non-blocking position responsive to the rotational movement. Each blocking element is able to engage the other one of the container and the dosing assembly. | 02-04-2010 |
| 20100030092 | Adaptive Hypoglycaemia Alert System and Method - The onset or presence of a hypoglycaemic condition in a living being is estimated by obtaining ECG signals, which are processed together with secondary input, such as skin impedance, information about a condition of the living being, or blood glucose level, to estimate whether the living being is experiencing or approaching a hypoglycaemic condition. An output alert may be generated. Feedback indicative of a possible misestimate of the onset or presence of the hypoglycaemic condition is received to allow a system incorporating the invention to adapt and personalize to a specific living being. The feedback may influence one or more sensitivity or specificity settings. Settings of the system may be influenced by the location or rate of movement of the living being. | 02-04-2010 |
| 20100029903 | Polypeptide Protracting Tags - The invention provides novel compounds comprising a protracting tag linked to therapeutically active compounds. | 02-04-2010 |
| 20100029721 | Pharmaceutical Formulation Comprising Metformin and Repaglinide - The invention is related to a pharmaceutical composition comprising repaglinide in combination with metformin or a salt thereof in unit dosage form wherein a pre-formulation of the repaglinide has a pH independent dissolution profile and a relative humidity of less than about 25% prior to mixing with the metformin or a salt thereof; and optionally one or more pharmaceutically acceptable excipients and to a method for its preparation. | 02-04-2010 |
| 20100022964 | Gearing Mechanism for an Injection Device - An injection device comprising: a base member ( | 01-28-2010 |
| 20100022456 | Dimeric Prolactin Receptor Ligands - The patent application relates to antagonistic dimers of prolactin molecules and their use in treating cancer. | 01-28-2010 |
| 20100022454 | Peptides with High Affinity for the Prolactin Receptor - The present invention is concerned with peptides binding to the prolactin receptor, wherein said peptides have an improved binding via binding site 1 (BS1) to the prolactin receptor. In one embodiment, said improved binding is achieved by mutation of positions 61, 71 and 73. | 01-28-2010 |
| 20100022446 | Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity. | 01-28-2010 |
| 20100016806 | Injection Device - An injection device for injection of set doses of medicine from a cartridge has a nut that is screwed up along a threaded piston rod during a dose setting operation. The nut is screwed along the piston rod by rotating a dose setting member. A rotational coupling mechanism includes an axially displaceable coupling member which is rotated as a function of axial displacement. During dose setting, the nut is allowed to rotate relative to the coupling member. During injection, the coupling member is rotationally locked to the nut. This provides a dose setting and injection mechanism wherein the nut member is both rotated during dose setting and during injection. | 01-21-2010 |
| 20100016238 | Peptides for Use in the Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity. | 01-21-2010 |
| 20100016237 | Novel Peptides for Use in the Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity. | 01-21-2010 |
| 20100015146 | TREATING DIABETES USING INHIBITORS OF IL-1 - The present invention describes a method of treating diabetes or metabolic syndrome with a compound that inhibits (a) IL-1, (b) the synthesis of IL-1, or (c) the release of IL-1. | 01-21-2010 |
| 20100012735 | Support for a Cartridge for Transferring an Electronically Readable Item of Information from the Cartridge to an Electronic Circuit - The invention relates to: A support ( | 01-21-2010 |
| 20100010455 | Medical Delivery System Adapted to be Locked Axially and Unlocked Rotationally - A medical delivery system ( | 01-14-2010 |
| 20100009989 | Urea Glucokinase Activators - This application relates to novel urea glucokinase activators and use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes. Further encompassed is a pharmaceutical composition comprising a compound according to the invention and a process for preparing such. | 01-14-2010 |
| 20100009899 | Novel Insulin Derivatives - The present invention relates to insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the α-amino group of the N-terminal amino acid residue of the B chain or to the ε-amino group of a Lys residue present in the B chain of the parent insulin, the side chain being of the general formula: | 01-14-2010 |
| 20100004907 | Methods of Optimizing Chromatographic Separation of Polypeptides - Described are methods for determination of peptide specific parameter(s) of a mixture comprising a target peptide and a related impurity (or impurities) to be used in a simulation model of chromatographic separation using mathematical model(s). Also described are chromatographic simulation methods using above determined parameters, as well as computer systems and computer programs for performing one or more of the above method(s). | 01-07-2010 |
| 20100004603 | Cartridge And Medical Delivery System Accommodating Such Cartridge - A cartridge having a distal end provided with a mechanical coding. The coding has the form of a circular protrusion where the circular outer diameter is dedicated a specific concentration of insulin contained in the cartridge. The distal end of the cartridge is fitted in to a circular contour in the housing. The outer diameter of the protrusion on the distal end of the cartridge is chosen as a larger diameter for a higher concentration of insulin. In this way only a cartridge containing the correct concentration or a lower concentration fits into a delivery system designed for a specific concentration of insulin. | 01-07-2010 |
| 20090318876 | Determination of a Type and an Amount of a Medicament by Inductive Means - The present invention relates to a medication delivery device ( | 12-24-2009 |
